Advertisement

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects

Published:November 02, 2021DOI:https://doi.org/10.1016/j.ejca.2021.09.029

      Highlights

      • Cabazitaxel is active in patients with metastatic castration resistant prostate cancer, regardless of the DNA damage repair status.
      • Overall survival was higher in DNA damage repair + men treated with cabazitaxel.
      • Efficacy of cabazitaxel may be lower in men previously treated with a poly(adenosine diphosphate–ribose) polymerase inhibitors.

      Abstract

      Background

      Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR) defects is unknown. With the advent of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) in partially overlapping indications with cabazitaxel, we aimed to determine cabazitaxel activity in men with mCRPC according to their DDR status.

      Methods

      This is a retrospective multicenter study that enrolled patients with mCRPC treated with cabazitaxel who had undergone DDR tumour tissue profiling. Patients with at least one deleterious germline or somatic alterations were considered DDR positive (DDR+). Each DDR + patient has been matched with a DDR negative (DDR-) from the same institution who underwent the same test. An exploratory cohort of patients found to be DDR + by liquid biopsy was also included. Prostate specific antigen (PSA) decline≥50% (PSA50), PSA progression-free survival (PFS, PSA-PFS), radiographic PFS (rPFS), clinical PFS or radiographic PFS (c/rPFS) and OS were evaluated.

      Results

      Among 190 men (95 DDR+, 95 DDR-) with tissue sequencing, PSA50 was achieved with cabazitaxel in 29/92 (32%) and 33/92 (36%) in patients with DDR+ and DDR- (P = 0.64). The median rPFS was 5.33 months [95%CI 4.34–7.04] versus 5.75 months [95%CI 4.67–7.27] (P = 0.55). The median OS was 15.4 months [95%CI 12.16–26.6] and 11.5 months [95%CI 9.76–14.4] (P = 0.036), respectively. No PSA50 responses on cabazitaxel were observed in BRCA1/2 patients previously treated with PARPi (n = 10). Similar outcomes with cabazitaxel were observed in the liquid biopsy cohort (n = 63 DDR+).

      Conclusions

      Our study suggests that cabazitaxel is active in patients with mCRPC regardless of their DDR status, although its activity in men pretreated with a PARPi may be lower.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Robinson D.
        • Van Allen E.M.
        • Wu Y.M.
        • Schultz N.
        • Lonigro R.J.
        • Mosquera J.M.
        • et al.
        Integrative clinical genomics of advanced prostate cancer.
        Cell. 2015; 162: 454
        • Pritchard C.C.
        • Mateo J.
        • Walsh M.F.
        • De Sarkar N.
        • Abida W.
        • Beltran H.
        • et al.
        Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
        N Engl J Med. 2016; 375: 443-453
        • Abida W.
        • Armenia J.
        • Gopalan A.
        • Brennan R.
        • Walsh M.
        • Barron D.
        • et al.
        Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making.
        JCO Precis Oncol. 2017; : 2017
        • de Bono J.S.
        • Fizazi K.
        • Saad F.
        • Shore N.
        • Sandhu S.K.
        • Mehra N.
        • et al.
        Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study.
        Ann Oncol. 2019; 30 (v328-v9)
        • Jonsson P.
        • Bandlamudi C.
        • Cheng M.L.
        • Srinivasan P.
        • Chavan S.S.
        • Friedman N.D.
        • et al.
        Tumour lineage shapes BRCA-mediated phenotypes.
        Nature. 2019; 571: 576-579
        • Castro E.
        • Goh C.
        • Olmos D.
        • Saunders E.
        • Leongamornlert D.
        • Tymrakiewicz M.
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Reimers M.A.
        • Yip S.M.
        • Zhang L.
        • Cieslik M.
        • Dhawan M.
        • Montgomery B.
        • et al.
        Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer.
        Eur Urol. 2020; 77: 333-341
        • Castro E.
        • Romero-Laorden N.
        • Del Pozo A.
        • Lozano R.
        • Medina A.
        • Puente J.
        • et al.
        PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2019; 37: 490-503
        • de Bono J.
        • Mateo J.
        • Fizazi K.
        • Saad F.
        • Shore N.
        • Sandhu S.
        • et al.
        Olaparib for metastatic castration-resistant prostate cancer.
        N Engl J Med. 2020; 382: 2091-2102
        • Hussain M.
        • Mateo J.
        • Fizazi K.
        • Saad F.
        • Shore N.
        • Sandhu S.
        • et al.
        Survival with olaparib in metastatic castration-resistant prostate cancer.
        N Engl J Med. 2020; 383: 2345-2357
        • Agarwal N.
        • Shore N.D.
        • Dunshee C.
        • Karsh L.I.
        • Sullivan B.
        • Santo N.D.
        • et al.
        Clinical and safety outcomes of TALAPRO-2: a two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).
        J Clin Oncol. 2019; 37: 5076
        • Smith M.R.
        • S S.K.
        • Kelly W.K.
        • Scher H.I.
        • Efstathiou E.
        • Lara P.N.
        • et al.
        Pre-specified interim analysis of GALAHAD: a phase 2 study of niraparib in patients with mCRPC and biallelic DNA-repair gene defects.
        Ann Oncol. 2019; 30: v851
        Version: v934
        • Abida W.
        • Patnaik A.
        • Campbell D.
        • Shapiro J.
        • Bryce A.H.
        • McDermott R.
        • et al.
        Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2020; 38: 3763-3772
        • de Bono J.S.
        • Mehra N.
        • Scagliotti G.V.
        • Castro E.
        • Dorff T.
        • Stirling A.
        • et al.
        Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
        Lancet Oncol. 2021; 22: 1250-1264
        • Nuhn P.
        • De Bono J.S.
        • Fizazi K.
        • Freedland S.J.
        • Grilli M.
        • Kantoff P.W.
        • et al.
        Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision Oncology.
        Eur Urol. 2019; 75: 88-99
        • de Wit R.
        • de Bono J.
        • Sternberg C.N.
        • Fizazi K.
        • Tombal B.
        • Wulfing C.
        • et al.
        Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer.
        N Engl J Med. 2019; 381: 2506-2518
        • Fizazi K.
        • Kramer G.
        • Eymard J.C.
        • Sternberg C.N.
        • de Bono J.
        • Castellano D.
        • et al.
        Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
        Lancet Oncol. 2020; 21: 1513-1525
        • Mateo J.
        • Cheng H.H.
        • Beltran H.
        • Dolling D.
        • Xu W.
        • Pritchard C.C.
        • et al.
        Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study.
        Eur Urol. 2018; 73: 687-693
        • Annala M.
        • Struss W.J.
        • Warner E.W.
        • Beja K.
        • Vandekerkhove G.
        • Wong A.
        • et al.
        Treatment outcomes and tumour loss of heterozygosity in germline DNA repair-deficient prostate cancer.
        Eur Urol. 2017; 72: 34-42
        • Isaacsson Velho P.
        • Qazi F.
        • Hassan S.
        • Carducci M.A.
        • Denmeade S.R.
        • Markowski M.C.
        • et al.
        Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects.
        Eur Urol. 2019; 76: 170-176
        • Kwon D.
        • Wright F.
        • Zhang L.
        • Chou J.
        • Borno H.
        • Desai A.
        • et al.
        Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.
        J Clin Oncol. 2020; 38: 187
        • Carlson A.S.
        • Acevedo R.
        • Lim D.M.
        • Gulati R.
        • Yu E.Y.
        • Schweizer M.T.
        Impact of DNA damage repair (DDR) mutations on treatment outcomes in men receiving conventional therapy for metastatic castration resistant prostate cancer (mCRPC).
        J Clin Oncol. 2020; 38: 172
        • Eisenberger M.
        • Hardy-Bessard A.C.
        • Kim C.S.
        • Géczi L.
        • Ford D.
        • Mourey L.
        • et al.
        Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA.
        J Clin Oncol. 2017; 35: 3198-3206
        • Gillessen S.
        • Attard G.
        • Beer T.M.
        • Beltran H.
        • Bjartell A.
        • Bossi A.
        • et al.
        Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019.
        Eur Urol. 2020; 77: 508-547
        • Scher H.I.
        • Morris M.J.
        • Stadler W.M.
        • Higano C.
        • Basch E.
        • Fizazi K.
        • et al.
        Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2016; 34: 1402-1418
        • Jovelet C.
        • Ileana E.
        • Le Deley M.C.
        • Motte N.
        • Rosellini S.
        • Romero A.
        • et al.
        Circulating cell-free tumour DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial.
        Clin Cancer Res : Off J Am Assoc Canc Res. 2016; 22: 2960-2968
        • Jensen K.
        • Konnick E.Q.
        • Schweizer M.T.
        • Sokolova A.O.
        • Grivas P.
        • Cheng H.H.
        • et al.
        Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference.
        JAMA Oncol. 2021; 7: 107-110
        • Abida DC W.
        • Patnaik A.
        • Sautois B.
        • Shapiro J.
        • Vogelzang N.J.
        • Bryce A.H.
        • et al.
        Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair deficient metastatic castration-resistant prostate cancer: updated analyses.
        Ann Oncol. 2019; (v325-v55)
        • Abida W.
        • Campbell D.
        • Patnaik A.
        • Shapiro J.D.
        • Sautois B.
        • Vogelzang N.J.
        • et al.
        Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study.
        Clin Cancer Res. 2020; 26: 2487-2496
        • Na R.
        • Zheng S.L.
        • Han M.
        • Yu H.
        • Jiang D.
        • Shah S.
        • et al.
        Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.
        Eur Urol. 2017; 71: 740-747